Home › Myeloproliferative Neoplasms › NCT06480591
Evaluation of the Pathobiology of CALR-mutated MPN Cells
RecruitingObservational studyHealthy volunteers welcome
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR). * Age ≥ 18 years at the time of enrollment * Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs * CALR-positive genetic mutation Exclusion Criteria: \- Diagnosis of MPN with JAK2 V617F mutation
About the study
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
What is being tested
- Blood Draw (other)
Sponsor: Wake Forest University Health Sciences · Participants: 35 · Started: Jan 21, 2025
Contact the study team
- Courtney Schepel · Phone: (980) 292-0817
Official record on ClinicalTrials.gov — NCT06480591
Locations in the U.S.
| North Carolina | Atrium Health Levine Cancer, Charlotte Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.